Diese Veranstaltung hat bereits stattgefunden


15th ISOPT Clinical 2019

International Symposium on Ocular Pharmacology and Therapeutics
46013 Valencia, Spanien
Veranstaltungsnummer: 32867
Gebühren ab: 500,00 €
verfügbare Plätze: unbegrenzt
Sprache: Deutsch

 Zum Kalender hinzufügen
  • Datum
    07.11.2019, 00:00 - 09.11.2019, 00:00
    Target Conferences
    The 15th ISOPT Clinical 2019 focuses on drugs and devices as part of the ophthalmologist tool box dealing with ailments of the eye. The symposium is addressed to clinicians, clinical trial researchers, members of the pharma industry as well as to regulatory officers. The event will focus on case presentations and international faculty will discuss cases reflecting new emerging treatments.


    Teilnehmer max.

    Gebühren ab
    600,00 €

    Earlybird bis 07.09.2019
    500,00 €
    - until September 7, 2019: €500
    - from September 7, 2019: €600
    - On-site: €700

    East European ophthalmologists ² :
    - until September 7, 2019: €400
    - from September 7, 2019: €500
    - On-site: €600

    Trainees (Residents, Fellows) ² :
    - until September 7, 2019: €400
    - from September 7, 2019: €450
    - On-site: €500

    ² Eastern European Delegates and Trainees must live and work in one of the following countries:
    Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, The Czech Republic, Estonia, Georgia, Hungary, Kosovo, Latvia, Lithuania, Montenegro, F.Y.R. Macedonia, Moldova, Poland, Romania, Russia, Serbia, Slovakia, Slovenia and Ukraine.
  • Tentative Program as at May 7, 2019


    Management AMD

    Part 1:  Present: Imaging and management in AMD

    Chairs: Anat Loewenstein, Israel & Paolo Lanzetta, Italy 

    Imaging/diagnosis/follow up

    Speakers: Luis Arias Barquet, Spain, Alfredo Garcia-Layana, Spain, Paolo Lanzetta, Italy, Stela Vujosevic, Italy 

    1. OCT angiography biomarkers in neovascular (remission or activity) AMD

    2. Imaging in dry AMD

    3. Non-exudative CNV; To treat or not?  

    4. Role of Microperimetry





    Speakers: Rufino Silva, Portugal, Maria Cristina Parravano, Italy, Karina Berg, Norway, Anat Loewenstein, Israel, Patricia Udaondo, Spain

    1. Managment of polipoydal lesions (Atlantic study)

    2. Latest evidence: RIVAL study

    3. TAE latest evidence with aflibercept (ALTAIR)

    4. Brolucizumab  Inquire with Novartis

    5. 2RT results in management of AMD: LEAD trial




    Part 2:  What´s next? What’s cooking in the industry kitchen

    Chairs: Barruch Kupperman, USA & Jordi Mones, Spain 

    Speakers: Barruch Kupperman, USA, Jordi Mones, Spain, Francine Behar-Cohen, France, Cedric Francois, USA, Anat Loewenstein, Israel, Francesco Boscia, Italy

    1. Abicipar  

    2. Faricimab

    3. Brimonidine in AMD

    4. Update on Complement inhibition results

    5. New studies in neovascular AMD (PDS,CCR3 nature)

    6. RPE transplant and other approaches




    Advanced AMD

    Chair: Usha Chakravarthy, UK 

    Speakers: Jordi Mones, Spain & Itay Chowers, Israel


    Review the pathogenesis of AMD and the pathways to CNV and GA  

    Examine current therapeutics and consider the long term outcomes and unmet need

    Evaluate the current therapeutic pipeline critically assessing the appropriateness of targets

    Designing new therapies with precision medicine in mind



    Diabetic Macular Edema

    Chairs: Patricia Udaondo, Spain & Stela Vujosevic, Italy


    Imaging in DME

    Speakers: Stela Vujosevic, Italy, Maria Cristina Parravano, Italy, Rufino Silva, Portugal 

    1. Prognostic and predictive biomarkers in DME

    2. Microvascular changes as predictor for DME progression

    3. Choroid as predictor for visual response to antiVEGF

    4. How can we define chronic DME?



    DME Management

    Speakers: Francesco Boscia, Italy, Albert Augustin, Germany / Usha Chakravarthy, UK, Anat Loewenstein, Israel, Patricia Udaondo, Spain, Paolo Lanzetta, Italy, Karina Berg, Norway


    Role of laser for treatment of DME and DR in the intravitreal therapy era.

    Real world evidence with fluocinolone implant in DME

    Long term efficacy and safety of Dexamethasone implant for DME.

    Real life outcomes of anti-VEGF therapy in DME: a review

    Take home messages of Protocol T

    Summary of EURETINA guidelines for DME.



    What is next in DME?

    J. Pablo Velazquez-Martin, USA

    1. Phase II trials that succeeded and fail for DME: angiopoietin vs Tie2

    2. Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate (ABC) with extended durability  

    3. Drugs in pipeline for DME.



    Diabetic Retinopathy

    Chairs: Francesco Bandello, Italy, & Rufino Silva, Portugal

    Speakers: Francesco Boscia, Italy, Javier Zarranz, Spain, Francesco Bandello, Italy, Rufino Silva, Portugal​

    1. Epidemiology and screening in DR

    2. OCT-A in patients without diabetic retinopathy

    3. Comparison of FA and OCTA in DR

    4. Ultrawidefield swept-source OCTA in DR

    5. Diabetic retinopathy treated with antiVEGF: results on clinical trials

    6. Update on DRCR.net studies in DR

    7. Is it safe to space out injections when you are treating PDR with anti-VEGF alone?

    Discussion and clinical cases

    Vein Occlusion

    Chairs: Albert Augustin, Germany & Alfredo García-Layana, Spain

    Speakers: Albert Augustin, Germany, Ibraheem EI Ghrably, Abu Dhabi, Alfredo García-Layana, Spain

    1. Multimodal imaging

    2. The LEAVO trial

    3. Long term efficacy of steroids in management of macular edema in vein Occlusion

    4. Latest evidence of anti VEGF in vein occlusion  

    5. Laser in vein occlusion: when and for what?





    Chairs: Jose García Arumí, Spain & Jose Maria Ruiz-Moreno, Spain 

    Speakers: Jose Maria Ruiz-Moreno, Spain, Maria Cristina Parravano, Italy / Francesco ​Bandello Italy, 

    Jose García-Arumí, Spain

    1. Myopic maculopathy; new classification

    2. Factors influencing visual acuity in patients receiving antiVEGF for myopic CNV

    3. Update on myopic CNV management

    4. When is surgery the option in myopic maculpathy? News on surgery in high myopic eyes.




    Chair: Ron Neumann, Israel

    Long Term systemic effects of Immunosuppressive drugs

    • Steroids

    • TNF inhibitors

    • Methotrexate

    • Celcept


    Total burden on health of systemic therapy

    Topical/systemic drugs decision making

    Allowing development of cataract vs. long term effects of systemic

    The art of discontinuing systemic therapy

    Vaccinations and epidemics in modern times and the immunosuppressed patient  


    Artificial Intelligence & Deep learning: Present or future?

    Chair: Tunde Peto, UK

    Speakers: Javier Zarranz, Spain, Leopold Schmetterer, Singapore, Dimitri Azar, USA​

    1. Introduction to AI and Deep learning: present and future

    2. Fight retina blindness.

    3. Home vision testing  

    4. Analysis in DR

    5. Future in imaging. Functional Imaging

    6. What is the position of industry in AI? (separated? Together?)




    Central Serous Choroidopathy

    Chairs: Francine Behar Cohen, France & Jose María Ruiz Moreno, Spain​




    GENE Therapy

    Chair: TBA

    Speakers: Itay Chowers, Israel, Jordi Mones, Spain, Marc de Smet, Switzerland, Usha Chakravarthy, UK,

    Dave Guyer, USA​

    1. Introduction to Gene and stem cell therapy

    2. International AMD genomic consortium.

    3. Stem cell therapy for AMD and Retinitis Pigmentosa. Where are we?

    4. Gene therapy for inherited retinal distrophies

    5. Gene therapy for AMD: RGX-314

    6. Surgeon´s view of Gene therapy approach: future of robot assistance




    Drug Delivery

    Chairs: Diane Tang Liu, USA & Uday Kompella, USA

    Speakers: Arup Das, USA, Rocio Herrero-Varnell, Spain, Vittoria Raffa, Italy, Mark Vezina, Canada, Angel Montero Carcaboso, Spain, Michael W. Stewart, USA, Diane Tang-Liu, USA,

    Uday Kompella, USA, Viral Kansara, USA

    Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Agents

    Microspheres as therapeutic systems to treat retinal diseases

    Nanoformulation as intraocular drug delivery system to target the posterior segment


    Targeted treatment of retinoblastoma with an oncolytic adenovirus

    Extended Duration Anti-VEGF therapy: the Promises and Disappointments

    Tunable duration of prolonged drug release from a novel formulation

    Biodegradable intraocular implants

    Clearside Biomedical, Inc., VP, Discovery



    Inhibition of Diabetic Retinopathy

    Chair: Arup Das

    Renu Kowluru, USA,  Edward Feener, USA, Susanne Mohr, USA, Ashwath Jayagopal, Switzerland

    Targeting G-proteins to inhibit Diabetic Retinopathy

    Kallikrein-Kinin System in Diabetic Retinopathy - Novel Target

    Targeting IL-6 Signaling to Intervene in the Progression of Diabetic Retinopathy

    Combotherapy of Diabetic Retinopathy: Emerging Paradigm




    Therapy of Retinal Angiogenesis

    Chair: Arup Das

    Subrata Chakarabarti, Canada, Julia Busik, USA, John Penn, USA, Debasish Sinha, USA

    Non-coding RNA based Therapeutics

    Control of Retinal Angiogenesis by modification of cell membrane lipid composition and membrane fluidity


    Glial influence in the pathogenesis of Diabetic Retinopathy

  • Science Museum Príncipe Felipe El Museu de les Ciències Príncipe Felipe

    Target Conferences
    65 Derech Menachem Begin
    IL - 6713818 Tel Aviv
    Tel.: +972 3 517 5150
    Fax: +972 3 517 5155


    Registration required. Please contact the organizer for further information.